BIOMAT Database Logo BIOMAT Database Logo

Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. 1997

G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
South-American Office for Anticancer Drug Development (SOAD), Hospital de Clinicas de Porto Alegre, RS, Brazil.

The authors report on the preliminary results of an ongoing phase II trial whereby the combination of the new DNA hypomethylating agent, 5-Aza-deoxycytidine (DAC), plus daunorubicin was given as first-line induction therapy to non-pretreated patients with acute myeloid leukemia (except FAB M3). DAC was given as a 4-h intravenous infusion at the dose of 90 mg/m2 daily from days 1-5, while daunorubicin was administered at the dose of 50 mg/m2 on days 1-3. A maximum of two courses were given to the patients with an interval of 4-6 weeks. Up to now, eight patients were accrued, of those six were evaluable for toxicity and response. The main toxic effects were bone marrow suppression, mucositis, nausea and vomiting, and alopecia. All six patients achieved a complete remission after one (five cases) or two (one case) courses. The trial is open for patient accrual.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716

Related Publications

G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
May 1993, Leukemia,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
May 1993, Leukemia,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients.
May 1993, Leukemia,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
July 2005, Seminars in hematology,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
August 2003, Cancer,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.
January 2014, Clinical epigenetics,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
January 2017, Yonsei medical journal,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia.
January 1985, Pharmacology & therapeutics,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
October 2005, Seminars in oncology,
G Schwartsmann, and M S Fernandes, and M D Schaan, and M Moschen, and L M Gerhardt, and L Di Leone, and B Loitzembauer, and L Kalakun
Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
January 2003, Drugs in R&D,
Copied contents to your clipboard!